Zacks Research Comments on Theravance Biopharma, Inc.’s Q1 2026 Earnings (NASDAQ:TBPH)

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Analysts at Zacks Research boosted their Q1 2026 earnings per share (EPS) estimates for shares of Theravance Biopharma in a research note issued to investors on Monday, April 15th. Zacks Research analyst K. Shah now forecasts that the biopharmaceutical company will post earnings per share of $0.29 for the quarter, up from their previous forecast of $0.25. The consensus estimate for Theravance Biopharma’s current full-year earnings is ($0.83) per share.

TBPH has been the subject of a number of other research reports. Evercore ISI cut shares of Theravance Biopharma from an “outperform” rating to an “inline” rating in a research note on Monday, January 8th. BTIG Research began coverage on Theravance Biopharma in a research note on Friday, April 12th. They issued a “buy” rating and a $21.00 price objective on the stock.

Theravance Biopharma Stock Down 2.3 %

NASDAQ:TBPH opened at $9.69 on Tuesday. The firm has a market cap of $470.55 million, a PE ratio of -9.99 and a beta of 0.36. Theravance Biopharma has a 12 month low of $8.21 and a 12 month high of $12.03. The company’s 50-day moving average price is $8.96 and its two-hundred day moving average price is $9.66.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Theravance Biopharma had a negative return on equity of 19.31% and a negative net margin of 96.12%. The firm had revenue of $17.57 million during the quarter, compared to the consensus estimate of $17.49 million.

Hedge Funds Weigh In On Theravance Biopharma

Large investors have recently bought and sold shares of the company. UBS Group AG boosted its stake in Theravance Biopharma by 45.0% in the 1st quarter. UBS Group AG now owns 3,549 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 1,101 shares during the period. Point72 Middle East FZE acquired a new position in shares of Theravance Biopharma during the 4th quarter worth approximately $41,000. Tower Research Capital LLC TRC grew its position in shares of Theravance Biopharma by 116.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,015 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 2,157 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Theravance Biopharma by 324.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,759 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 4,402 shares during the period. Finally, Royal Bank of Canada raised its position in shares of Theravance Biopharma by 33.8% in the second quarter. Royal Bank of Canada now owns 6,532 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 1,649 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.